- ►aspetjournals.org A Inui - Pharmacological reviews, 2000 - ASPET Energy homeostasis is accomplished through a highly integrated and redundant
neurohumoral system. Recently, novel molecular mediators and regulatory pathways
for feeding and body weight regulation have been identified in the brain ... Cited by 126 - Related articles - BL Direct - All 4 versions
C Gauthier, D Langin, JL Balligand - Trends in Pharmacological Sciences, 2000 - Elsevier The β 3 -adrenoceptor is a G-protein-coupled seven-transmembrane domain
receptor (GPCR) activated by catecholamines. The β 3 -adrenoceptors have been
studied in cells that express recombinant receptors or high levels of ... Cited by 109 - Related articles - BL Direct - All 7 versions
- ►nih.gov P Varghese, RW Harrison, RA Lofthouse, D … - Journal of Clinical Investigation, 2000 - Am Soc Clin Investig The cardiac β-adrenergic pathway potently stimulates myocardial performance,
thereby providing a mechanism for myocardial contractile reserve. β-Adrenergic
activation also increases cardiac nitric oxide (NO) production, which ... Cited by 81 - Related articles - BL Direct - All 4 versions
- ►aspetjournals.org AA Konkar, Y Zhai, JG Granneman - Molecular Pharmacology, 2000 - ASPET CGP 12177 is a -adrenergic receptor (AR) ligand that has been used to
characterize the 3-AR and the putative 4-AR. The ability of CGP 12177 to
activate 1-AR when overexpressed in vitro and the presence of 1-AR in ... Cited by 77 - Related articles - BL Direct - All 3 versions
O Boss, E Bachman, A Vidal-Puig, CY Zhang, … - Biochemical and Biophysical Research …, 1999 - Elsevier Administration of β-adrenergic receptor (β-AR) agonists, especially β 3 -AR
agonists, is well known to increase thermogenesis in rodents and humans. In this
work we studied the role of the β 3 -AR in regulating mRNA expression of ... Cited by 72 - Related articles - All 5 versions
- ►suarez.com [PDF] JRS Arch - European journal of pharmacology, 2002 - Elsevier Although the β 3 -adrenoceptor was not cloned until 1989 (Emorine et al.,
1989), it had already been apparent for 5 or 6 years that agonists of this
receptor might have potential in the treatment of obesity and Type 2 ... Cited by 71 - Related articles - All 6 versions
JC Clapham, JRS Arch, M Tadayyon - Pharmacology and Therapeutics, 2001 - Elsevier The last 25 years have seen a great increase in the incidence of obesity, both
in the Western world and in developing third world countries. Despite the
seeming inexorable progression of this disease, there have been limited ... Cited by 71 - Related articles - All 3 versions
- ►physiology.org JG Granneman - American Journal of Physiology- Endocrinology And …, 2001 - Am Physiological Soc Pharmacological data have accumulated over the past twenty-five years to support
the existence of atypical -adrenergic receptors (AR). A defining feature of
these receptors is the relatively low potency of standard -AR antagonists, ... Cited by 60 - Related articles - BL Direct - All 3 versions
- ►jbc.org BB Lowell, ES Bachman - Journal of Biological Chemistry, 2003 - ASBMB Fat is stored when the number of calories consumed exceeds the number of
calories expended. In principle, obesity could be caused by increased food
intake or decreased energy expenditure or from a combination of the two. ... Cited by 56 - Related articles - BL Direct - All 4 versions
M Leonhardt, B Hrupka, W Langhans - European Journal of Nutrition, 1999 - Springer Summary Many new substances are currently being investigated for their
usefulness in the pharmaco- therapy of obesity. Most drugs interfere with
monoamine neuro- transmitter (serotonin, noradrenalin, dopamine and ... Cited by 43 - Related articles - BL Direct - All 4 versions
